These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797 [TBL] [Abstract][Full Text] [Related]
7. Current status of local therapy in malignant gliomas--a clinical review of three selected approaches. Juratli TA; Schackert G; Krex D Pharmacol Ther; 2013 Sep; 139(3):341-58. PubMed ID: 23694764 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma. Zylber-Katz E; Gomori JM; Schwartz A; Lossos A; Bokstein F; Siegal T Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645 [TBL] [Abstract][Full Text] [Related]
9. Blood-brain barrier and treatment of central nervous system tumors. Wiranowska M J Fla Med Assoc; 1992 Oct; 79(10):707-10. PubMed ID: 1460453 [TBL] [Abstract][Full Text] [Related]
10. Blood-brain barrier disruption in the treatment of brain tumors. Blanchette M; Fortin D Methods Mol Biol; 2011; 686():447-63. PubMed ID: 21082387 [TBL] [Abstract][Full Text] [Related]
11. The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery. Dahlborg SA; Petrillo A; Crossen JR; Roman-Goldstein S; Doolittle ND; Fuller KH; Neuwelt EA Cancer J Sci Am; 1998; 4(2):110-24. PubMed ID: 9532413 [TBL] [Abstract][Full Text] [Related]
13. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art. Karim R; Palazzo C; Evrard B; Piel G J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752 [TBL] [Abstract][Full Text] [Related]
14. Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors. Neuwelt EA; Rapoport SI Fed Proc; 1984 Feb; 43(2):214-9. PubMed ID: 6692941 [TBL] [Abstract][Full Text] [Related]
15. New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting. Doolittle ND; Abrey LE; Bleyer WA; Brem S; Davis TP; Dore-Duffy P; Drewes LR; Hall WA; Hoffman JM; Korfel A; Martuza R; Muldoon LL; Peereboom D; Peterson DR; Rabkin SD; Smith Q; Stevens GH; Neuwelt EA Clin Cancer Res; 2005 Jan; 11(2 Pt 1):421-8. PubMed ID: 15701824 [TBL] [Abstract][Full Text] [Related]
16. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Kemper EM; Boogerd W; Thuis I; Beijnen JH; van Tellingen O Cancer Treat Rev; 2004 Aug; 30(5):415-23. PubMed ID: 15245774 [TBL] [Abstract][Full Text] [Related]
17. Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Rapoport SI Cell Mol Neurobiol; 2000 Apr; 20(2):217-30. PubMed ID: 10696511 [TBL] [Abstract][Full Text] [Related]
18. Blood-brain barrier disruption for the treatment of malignant brain tumors: The National Program. Doolittle ND; Petrillo A; Bell S; Cummings P; Eriksen S J Neurosci Nurs; 1998 Apr; 30(2):81-90. PubMed ID: 9642616 [TBL] [Abstract][Full Text] [Related]
19. [Pharmacologic bases of chemotherapy of brain tumors in children]. Vassal G Bull Cancer; 1990; 77(7):699-713. PubMed ID: 2207360 [TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Doolittle ND; Miner ME; Hall WA; Siegal T; Jerome E; Osztie E; McAllister LD; Bubalo JS; Kraemer DF; Fortin D; Nixon R; Muldoon LL; Neuwelt EA Cancer; 2000 Feb; 88(3):637-47. PubMed ID: 10649259 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]